Aarti Pharmalabs Q1 FY27 PAT up 49% YoY to Rs.71 cr, Rs.149 cr capex cleared
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue grew 42% YoY to Rs.535 cr, PAT rose 49% to Rs.71 cr, EPS at Rs.7.87. Consolidated PAT jumped 65% to Rs.76 cr. Board cleared Rs.149 cr capex for a new Intermediate Block of 405 KL capacity to serve intermediate and CDMO customers, funded by internal accruals and borrowings. Rashesh Gogri to move from Non-Executive Director to Managing Director, while Hetal Gogri Gala shifts from MD to Executive Director, effective Oct 1. Auditor flagged an emphasis of matter on restatement of Q1 FY26 figures for an FX derivative fair value loss of Rs.4.6 cr.
Strong quarterly growth and capacity expansion point to future revenue, but leadership reshuffle and restated prior-year numbers may draw investor attention.